In vivo near-infrared imaging and phototherapy of tumors using a cathepsin B-activated fluorescent probe.

[1]  B. Liu,et al.  g-C3N4 Coated Upconversion Nanoparticles for 808 nm Near-Infrared Light Triggered Phototherapy and Multiple Imaging , 2016 .

[2]  Jiangli Fan,et al.  Recent Development of Chemosensors Based on Cyanine Platforms. , 2016, Chemical reviews.

[3]  Song Hu,et al.  Gold Nanoparticle Coated Carbon Nanotube Ring with Enhanced Raman Scattering and Photothermal Conversion Property for Theranostic Applications. , 2016, Journal of the American Chemical Society.

[4]  Wei Pan,et al.  A nuclear targeted dual-photosensitizer for drug-resistant cancer therapy with NIR activated multiple ROS† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6sc00737f , 2016, Chemical science.

[5]  P. Loadman,et al.  Proteases in cancer drug delivery. , 2016, Advanced drug delivery reviews.

[6]  Peng Huang,et al.  Tumor-Specific Formation of Enzyme-Instructed Supramolecular Self-Assemblies as Cancer Theranostics. , 2015, ACS nano.

[7]  Chun-Hua Yan,et al.  Multifunctional upconversion–nanoparticles–trismethylpyridylporphyrin–fullerene nanocomposite: a near-infrared light-triggered theranostic platform for imaging-guided photodynamic therapy , 2015 .

[8]  A. Scherz,et al.  Photodynamic Quenched Cathepsin Activity Based Probes for Cancer Detection and Macrophage Targeted Therapy , 2015, Theranostics.

[9]  Hao Cheng,et al.  Hydrophobic IR780 encapsulated in biodegradable human serum albumin nanoparticles for photothermal and photodynamic therapy. , 2015, Acta biomaterialia.

[10]  Jinhui Wu,et al.  Activatable photodynamic destruction of cancer cells by NIR dye/photosensitizer loaded liposomes. , 2015, Chemical communications.

[11]  Ping Gong,et al.  Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy. , 2014, ACS nano.

[12]  Shiran Ferber,et al.  Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release. , 2014, Cancer letters.

[13]  Zhuang Liu,et al.  Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy. , 2014, Biomaterials.

[14]  Shiran Ferber,et al.  Synthesis and evaluation of new NIR-fluorescent probes for cathepsin B: ICT versus FRET as a turn-ON mode-of-action. , 2014, Bioorganic & medicinal chemistry letters.

[15]  J. Ong,et al.  Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. , 2014, Molecular pharmaceutics.

[16]  U. Weidle,et al.  Proteases as activators for cytotoxic prodrugs in antitumor therapy. , 2014, Cancer genomics & proteomics.

[17]  Juyoung Yoon,et al.  Recent progress in the development of near-infrared fluorescent probes for bioimaging applications. , 2014, Chemical Society reviews.

[18]  S. Kemmochi,et al.  In vivo imaging of tissue-remodeling activity involving infiltration of macrophages by a systemically administered protease-activatable probe in colon cancer tissues. , 2013, Translational oncology.

[19]  M. Bogyo,et al.  Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. , 2013, Journal of the American Chemical Society.

[20]  Yan-jun Zhong,et al.  Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy , 2012, International journal of oncology.

[21]  Jianping Zhou,et al.  A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. , 2012, Biomaterials.

[22]  Juyoung Yoon,et al.  Fluorescent chemosensors based on spiroring-opening of xanthenes and related derivatives. , 2012, Chemical reviews.

[23]  J. Joyce,et al.  Proteolytic networks in cancer. , 2011, Trends in cell biology.

[24]  Kalpna Garkhal,et al.  Doxorubicin-loaded (PEG)₃-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study. , 2011, Molecular pharmaceutics.

[25]  Tayyaba Hasan,et al.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. , 2010, Chemical reviews.

[26]  Gang Zheng,et al.  Activatable photosensitizers for imaging and therapy. , 2010, Chemical reviews.

[27]  G. Kroemer,et al.  Lysosomal membrane permeabilization in cell death , 2008, Oncogene.

[28]  Georges von Degenfeld,et al.  Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. , 2007, Nature chemical biology.

[29]  B. Wilson,et al.  Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation , 2007, Proceedings of the National Academy of Sciences.

[30]  R. Weissleder,et al.  Selective antitumor effect of novel protease-mediated photodynamic agent. , 2006, Cancer research.

[31]  M. Beauchemin,et al.  Caspase- and mitochondrial dysfunction-dependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis , 2005, Leukemia.

[32]  Bonnie F. Sloane,et al.  Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. , 2005, Seminars in cancer biology.

[33]  J. Castro,et al.  Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Izabela Berdowska,et al.  Cysteine proteases as disease markers. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[35]  Vishal Saxena,et al.  Degradation kinetics of indocyanine green in aqueous solution. , 2003, Journal of pharmaceutical sciences.

[36]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[37]  Bonnie F. Sloane,et al.  Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. , 1994, The American journal of pathology.

[38]  Zhengze Yu,et al.  d dual-photosensitizer for drug-resistant cancer therapy with NIR activated multiple ROS † , 2016 .

[39]  Bonnie F. Sloane,et al.  Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.